Ankit Mahadevia - Feb 1, 2022 Form 4 Insider Report for Spero Therapeutics, Inc. (SPRO)

Role
CEO and President, Director
Signature
/s/ Tamara Joseph, Attorney-in-Fact for Ankit Mahadevia
Stock symbol
SPRO
Transactions as of
Feb 1, 2022
Transactions value $
$0
Form type
4
Date filed
2/3/2022, 03:18 PM
Previous filing
Dec 29, 2021
Next filing
Feb 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRO Common Stock Award $0 +134K +93.15% $0.00 278K Feb 1, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRO Stock Option (Right to Buy) Award $0 +188K $0.00 188K Feb 1, 2022 Common Stock 188K $11.18 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2023, subject to the Reporting Person's continued service through the applicable vesting date.
F2 Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Amount also includes 212,387 RSUs held by the Reporting Person.
F3 The shares underlying this option vest as to 25% on February 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.